This content is not available in your region

AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer

Access to the comments Comments
By Reuters
AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid   -   Copyright  Brendan McDermid(Reuters)

(Reuters) – British drugmaker AstraZeneca Plc <AZN.L> said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.

The company said the FDA accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer.

A final decision is expected in the first quarter of 2020.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)